Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics

Area of Science:

• Pharmacology
• Endocrinology
• Biochemistry

Background:

• Type 2 diabetes mellitus (T2DM) is a growing global health concern requiring innovative therapeutic strategies.
• Existing antidiabetic agents often require frequent administration, impacting patient adherence and treatment efficacy.
• Exendin-4 analogs show promise but often suffer from short in vivo half-lives.

Purpose of the Study:

• To design and characterize a novel, long-acting Exendin-4 derivative (LEx4) for improved T2DM management.
• To evaluate the in vitro stability and in vivo pharmacokinetic and pharmacodynamic properties of LEx4.
• To assess the therapeutic potential of LEx4 in preclinical models of T2DM.

Main Methods:

• LEx4 was synthesized and purified (>99% purity).
• Albumin binding affinity was determined using microscale thermophoresis (MST).
• In vitro stability in plasma and in vivo efficacy (OGTT, body weight, glucose tolerance) were assessed in diabetic mouse models and Sprague Dawley rats.

Main Results:

• LEx4 exhibited high-affinity binding to serum albumin (K_a ≈ 1.3-1.5 × 10⁶ M^-1).
• LEx4 demonstrated enhanced stability against proteases in rat and human plasma compared to native Exendin-4.
• In vivo studies showed dose-dependent glucose-lowering efficacy, prolonged half-life (3.3-fold longer in rats), and sustained beneficial effects on metabolic parameters in diabetic mice.

Conclusions:

• LEx4 possesses superior pharmaceutical potential as a long-acting therapeutic agent for T2DM.
• The albumin-binding strategy is effective for developing long-acting peptide-based drugs.
• LEx4 offers a promising new avenue for T2DM treatment with improved pharmacokinetic and pharmacodynamic profiles.